person · Reporting owner

Manning Anthony M.

Disclosed activity across 3 companies

Tapewire entity: 34399
SEC CIK: 0001716468

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Monte Rosa Therapeutics, Inc.GLUE · Entity 4828	Director	June 29, 2026	June 30, 2026
PALATIN TECHNOLOGIES INCPTN · Entity 7649	Director	July 15, 2024	July 16, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Monte Rosa Therapeutics, Inc.

Report date June 29, 2026 · Filed June 30, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2026-06-29 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-06-29 · Exercise / conversion · Acquired 10,000 · Balance 10,000 Row 2 · 2026-06-29 · Sale · Disposed 10,000 · Balance 0
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.16 · Expires 2034-06-12	Direct	2,100	Reported balance After 2026-06-29 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-29 · Exercise / conversion · Disposed 10,000 · Balance 2,100 F1: The shares underlying this option are fully vested and exercisable.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option are fully vested and exercisable.

PALATIN TECHNOLOGIES INC

Report date July 15, 2024 · Filed July 16, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	36,080	Reported balance After 2024-07-15 transaction · row 1 1 source row Row 1 · 2024-07-15 · Grant · Acquired 12,000 · Balance 36,080 F1: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest on June 4, 2025. The restricted share units were granted by the Compensation Committee on June 4, 2024, which grant was subject to certification by the Chief Financial Officer that the shareholders had increased the shares reserved under the 2011 Stock Incentive Plan, and that there were no impediments to the grant of the options. The required certification was made on July 15, 2024.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.83 · Expires 2034-06-04	Direct	54,280	Reported balance After 2023-07-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-07-15 · Grant · Acquired 17,000 · Balance 54,280 F2: The option vests on June 4, 2025, and in the event that the director does not serve until June 30, 2025, is prorated based on the period of service at the rate of 1/12 per month on the last day of each month, starting on July 31, 2024. The options were granted by the Compensation Committee on June 4, 2024, which grant was subject to certification by the Chief Financial Officer that the shareholders had increased the shares reserved under the 2011 Stock Incentive Plan, and that there were no impediments to the grant of the options. The required certification was made on July 15, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest on June 4, 2025. The restricted share units were granted by the Compensation Committee on June 4, 2024, which grant was subject to certification by the Chief Financial Officer that the shareholders had increased the shares reserved under the 2011 Stock Incentive Plan, and that there were no impediments to the grant of the options. The required certification was made on July 15, 2024.

F2: The option vests on June 4, 2025, and in the event that the director does not serve until June 30, 2025, is prorated based on the period of service at the rate of 1/12 per month on the last day of each month, starting on July 31, 2024. The options were granted by the Compensation Committee on June 4, 2024, which grant was subject to certification by the Chief Financial Officer that the shareholders had increased the shares reserved under the 2011 Stock Incentive Plan, and that there were no impediments to the grant of the options. The required certification was made on July 15, 2024.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

MOMENTA PHARMACEUTICALS INC

Report date October 01, 2020 · Filed October 01, 2020

Section 16 reporting ended · disclosed 2020-10-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-10-01 transaction · row 1 1 source row Row 1 · 2020-10-01 · Disposition to issuer · Disposed 12,778 · Balance 0 F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2020-10-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-10-01 · Disposition to issuer · Disposed 45,000 · Balance 0 F2: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2020-10-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-10-01 · Disposition to issuer · Disposed 1,500 · Balance 0 F2: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2020-10-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-10-01 · Disposition to issuer · Disposed 31,500 · Balance 0 F2: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2020-10-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-10-01 · Disposition to issuer · Disposed 45,000 · Balance 0 F2: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.85 · Expires 2027-02-07	Direct	Reported balance After 2020-10-01 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-10-01 · Disposition to issuer · Disposed 13,258 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.76 · Expires 2029-02-11	Direct	Reported balance After 2020-10-01 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-10-01 · Disposition to issuer · Disposed 20,082 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.87 · Expires 2030-02-07	Direct	Reported balance After 2020-10-01 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-10-01 · Disposition to issuer · Disposed 3,622 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.02 · Expires 2025-02-18	Direct	Reported balance After 2020-10-01 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-10-01 · Disposition to issuer · Disposed 5,841 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.02 · Expires 2025-02-18	Direct	Reported balance After 2020-10-01 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2020-10-01 · Disposition to issuer · Disposed 73 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.83 · Expires 2026-02-09	Direct	Reported balance After 2020-10-01 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2020-10-01 · Disposition to issuer · Disposed 3,751 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.83 · Expires 2026-02-09	Direct	Reported balance After 2020-10-01 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2020-10-01 · Disposition to issuer · Disposed 1,499 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.85 · Expires 2027-02-07	Direct	Reported balance After 2020-10-01 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2020-10-01 · Disposition to issuer · Disposed 3,242 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.76 · Expires 2029-02-11	Direct	Reported balance After 2020-10-01 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2020-10-01 · Disposition to issuer · Disposed 52,793 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.87 · Expires 2030-02-07	Direct	Reported balance After 2020-10-01 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2020-10-01 · Disposition to issuer · Disposed 86,378 · Balance 0 F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price.

F2: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price.

F3: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 16, 2020 Filed Jun 18, 2020 21:05 UTC	PALATIN TECHNOLOGIES INC PTN · Entity 7649	GrantCommon Stock	73,000	$0.00	$0.00	Disclosure SEC source: 0001654954-20-006796 · section16.xml · nonDerivative · entry 1 Manning Anthony M. · CIK 0001716468 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,583 F1 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest on June 16, 2021. F1 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest on June 16, 2021. Read SEC document
June 12, 2020 Filed Jun 15, 2020 17:25 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	6,756	$30.15	$203,693.40	Disclosure SEC source: 0001179110-20-007361 · edgar.xml · nonDerivative · entry 2 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,002 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
June 11, 2020 Filed Jun 15, 2020 17:25 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	GrantRestricted Stock Units · Derivative	15,000	$0.00	$0.00	Disclosure SEC source: 0001179110-20-007361 · edgar.xml · derivative · entry 3 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of MNTA Common Stock. F4 · derivative.exercise_date: Subject to the officer's continued employment with the company, 15,000 Restricted Stock Units will vest on June 11, 2021. F4 · derivative.expiration_date: Subject to the officer's continued employment with the company, 15,000 Restricted Stock Units will vest on June 11, 2021. Read SEC document
June 11, 2020 Filed Jun 15, 2020 17:25 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	GrantCommon Stock	15,000	$0.00	$0.00	Disclosure SEC source: 0001179110-20-007361 · edgar.xml · nonDerivative · entry 1 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,758 F1 · kind: Shares received pursuant to settlement of Performance Stock Units that were granted on October 17, 2018. Read SEC document
May 11, 2020 Filed May 12, 2020 16:49 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	414	$33.75	$13,972.50	Disclosure SEC source: 0001179110-20-005772 · edgar.xml · nonDerivative · entry 1 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,758 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $33.10 to $34.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
May 08, 2020 Filed May 11, 2020 16:22 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	336	$33.30	$11,188.80	Disclosure SEC source: 0001179110-20-005718 · edgar.xml · nonDerivative · entry 2 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,172 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
May 07, 2020 Filed May 11, 2020 16:22 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionRestricted Stock Units · Derivative	750	$0.00	$0.00	Disclosure SEC source: 0001179110-20-005718 · edgar.xml · derivative · entry 3 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,250 Underlying: Common Stock · 750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on February 7, 2017. F4 · derivative.exercise_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. F4 · derivative.expiration_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. Read SEC document
May 07, 2020 Filed May 11, 2020 16:22 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionCommon Stock	750	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-20-005718 · edgar.xml · nonDerivative · entry 1 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,508 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on February 7, 2017. F2 · price: Restricted Stock Units convert into common stock on a one-for-one basis. Read SEC document
April 21, 2020 Filed Apr 22, 2020 16:08 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	1,886	$30.55	$57,617.30	Disclosure SEC source: 0001179110-20-005044 · edgar.xml · nonDerivative · entry 1 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,758 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person December 14, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.31 to $30.82. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
April 20, 2020 Filed Apr 21, 2020 16:19 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	1,614	$28.96	$46,741.44	Disclosure SEC source: 0001179110-20-004998 · edgar.xml · nonDerivative · entry 2 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,644 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
April 17, 2020 Filed Apr 21, 2020 16:19 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionRestricted Stock Units · Derivative	3,500	$0.00	$0.00	Disclosure SEC source: 0001179110-20-004998 · edgar.xml · derivative · entry 3 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 3,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on October 17, 2018. F4 · derivative.exercise_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. F4 · derivative.expiration_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. Read SEC document
April 17, 2020 Filed Apr 21, 2020 16:19 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionCommon Stock	3,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-20-004998 · edgar.xml · nonDerivative · entry 1 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on October 17, 2018. F3 · price: Restricted Stock Units convert into common stock on a one-for-one basis. Read SEC document
March 06, 2020 Filed Mar 9, 2020 17:15 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	7,310	$29.00	$211,990.00	Disclosure SEC source: 0001179110-20-003312 · edgar.xml · nonDerivative · entry 2 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,758 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
March 05, 2020 Filed Mar 9, 2020 17:15 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	GrantRestricted Stock Units · Derivative	15,000	$0.00	$0.00	Disclosure SEC source: 0001179110-20-003312 · edgar.xml · derivative · entry 3 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of MNTA Common Stock. F4 · derivative.exercise_date: Subject to the officer's continued employment with the company, the Restricted Stock Units will vest on March 5, 2021. F4 · derivative.expiration_date: Subject to the officer's continued employment with the company, the Restricted Stock Units will vest on March 5, 2021. Read SEC document
March 05, 2020 Filed Mar 9, 2020 17:15 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	GrantCommon Stock	15,000	$0.00	$0.00	Disclosure SEC source: 0001179110-20-003312 · edgar.xml · nonDerivative · entry 1 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,068 F1 · kind: Shares received pursuant to settlement of Performance Stock Units that were granted on October 17, 2018. Read SEC document
February 18, 2020 Filed Feb 20, 2020 17:06 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	16,459	$32.56	$535,905.04	Disclosure SEC source: 0001179110-20-001974 · edgar.xml · nonDerivative · entry 1 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,068 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $31.48 to $33.43 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
February 13, 2020 Filed Feb 14, 2020 18:54 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	8,541	$30.03	$256,486.23	Disclosure SEC source: 0001179110-20-001668 · edgar.xml · nonDerivative · entry 2 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,316 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan. Read SEC document
February 12, 2020 Filed Feb 14, 2020 18:54 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionRestricted Stock Units · Derivative	25,000	$0.00	$0.00	Disclosure SEC source: 0001179110-20-001668 · edgar.xml · derivative · entry 4 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on February 12, 2018. F5 · derivative.exercise_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 50% of the shares on the first anniversary of the grant date, and the remaining 50% will vest on the second anniversary of the grant date. F5 · derivative.expiration_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 50% of the shares on the first anniversary of the grant date, and the remaining 50% will vest on the second anniversary of the grant date. Read SEC document
February 12, 2020 Filed Feb 14, 2020 18:54 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	789	$31.63	$24,956.07	Disclosure SEC source: 0001179110-20-001668 · edgar.xml · nonDerivative · entry 3 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,527 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $31.23 to $31.99 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
February 12, 2020 Filed Feb 14, 2020 18:54 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionCommon Stock	25,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-20-001668 · edgar.xml · nonDerivative · entry 1 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,857 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on February 12, 2018. F2 · price: Restricted Stock Units convert into common stock on a one-for-one basis. Read SEC document
February 11, 2020 Filed Feb 12, 2020 17:28 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	112	$32.23	$3,609.76	Disclosure SEC source: 0001179110-20-001524 · edgar.xml · nonDerivative · entry 1 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,857 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
February 10, 2020 Filed Feb 11, 2020 19:01 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	224	$31.50	$7,056.00	Disclosure SEC source: 0001179110-20-001467 · edgar.xml · nonDerivative · entry 2 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,969 F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
February 07, 2020 Filed Feb 11, 2020 19:01 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionRestricted Stock Units · Derivative	750	$0.00	$0.00	Disclosure SEC source: 0001179110-20-001467 · edgar.xml · derivative · entry 5 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on February 7, 2017. F3 · derivative.exercise_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. F3 · derivative.expiration_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. Read SEC document
February 07, 2020 Filed Feb 11, 2020 19:01 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	GrantStock Option (Right to Buy) · Derivative	90,000	$0.00 Strike: $31.87	$0.00	Disclosure SEC source: 0001179110-20-001467 · edgar.xml · derivative · entry 4 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2030-02-07 F5 · shares: Represents options granted by the issuer pursuant to the issuer's 2013 Incentive Award Plan, as amended and restated. F6 · derivative.exercise_date: Subject to certain criteria, the stock option will vest and become exercisable with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. Read SEC document
February 07, 2020 Filed Feb 11, 2020 19:01 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	GrantRestricted Stock Units · Derivative	45,000	$0.00	$0.00	Disclosure SEC source: 0001179110-20-001467 · edgar.xml · derivative · entry 3 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires not disclosed F2 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. F3 · derivative.expiration_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. Read SEC document
February 07, 2020 Filed Feb 11, 2020 19:01 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionCommon Stock	750	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-20-001467 · edgar.xml · nonDerivative · entry 1 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,193 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on February 7, 2017. F2 · price: Restricted Stock Units convert into common stock on a one-for-one basis. Read SEC document
January 22, 2020 Filed Jan 24, 2020 16:40 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	227	$29.02	$6,587.54	Disclosure SEC source: 0001179110-20-000760 · edgar.xml · nonDerivative · entry 2 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,443 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person December 14, 2018. F3 · price: This transaction was executed in multiple trades at prices ranging from $28.87 to $29.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
January 22, 2020 Filed Jan 24, 2020 16:40 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	2,038	$29.01	$59,122.38	Disclosure SEC source: 0001179110-20-000760 · edgar.xml · nonDerivative · entry 1 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,670 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person December 14, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $28.81 to $29.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
January 21, 2020 Filed Jan 22, 2020 17:17 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	1,235	$30.08	$37,148.80	Disclosure SEC source: 0001179110-20-000703 · edgar.xml · nonDerivative · entry 2 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,708 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
January 17, 2020 Filed Jan 22, 2020 17:17 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionRestricted Stock Units · Derivative	3,500	$0.00	$0.00	Disclosure SEC source: 0001179110-20-000703 · edgar.xml · derivative · entry 3 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,500 Underlying: Common Stock · 3,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on October 17, 2018. F4 · derivative.exercise_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. F4 · derivative.expiration_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. Read SEC document
January 17, 2020 Filed Jan 22, 2020 17:17 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionCommon Stock	3,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-20-000703 · edgar.xml · nonDerivative · entry 1 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on October 17, 2018. F3 · price: Restricted Stock Units convert into common stock on a one-for-one basis. Read SEC document
January 15, 2020 Filed Jan 17, 2020 16:14 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionStock Option (Right to Buy) · Derivative	7,500	$0.00 Strike: $18.85	$0.00	Disclosure SEC source: 0001179110-20-000653 · edgar.xml · derivative · entry 6 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 7,500 shares Expires 2027-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person December 14, 2018. Read SEC document
January 15, 2020 Filed Jan 17, 2020 16:14 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionStock Option(Right to Buy) · Derivative	17,541	$0.00 Strike: $17.96	$0.00	Disclosure SEC source: 0001179110-20-000653 · edgar.xml · derivative · entry 5 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,541 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person December 14, 2018. Read SEC document
January 15, 2020 Filed Jan 17, 2020 16:14 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionStock Option(Right to Buy) · Derivative	4,073	$0.00 Strike: $17.96	$0.00	Disclosure SEC source: 0001179110-20-000653 · edgar.xml · derivative · entry 4 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,073 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person December 14, 2018. Read SEC document
January 15, 2020 Filed Jan 17, 2020 16:14 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	29,114	$28.44	$828,002.16	Disclosure SEC source: 0001179110-20-000653 · edgar.xml · nonDerivative · entry 3 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,443 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person December 14, 2018. Read SEC document
January 15, 2020 Filed Jan 17, 2020 16:14 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionCommon Stock	7,500	$18.85	$141,375.00	Disclosure SEC source: 0001179110-20-000653 · edgar.xml · nonDerivative · entry 2 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person December 14, 2018. Read SEC document
January 15, 2020 Filed Jan 17, 2020 16:14 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionCommon Stock	21,614	$17.96	$388,187.44	Disclosure SEC source: 0001179110-20-000653 · edgar.xml · nonDerivative · entry 1 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person December 14, 2018. Read SEC document
December 24, 2019 Filed Dec 27, 2019 16:59 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionStock Option (Right to Buy) · Derivative	6,750	$0.00 Strike: $10.83	$0.00	Disclosure SEC source: 0001179110-19-013163 · edgar.xml · derivative · entry 9 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,499 Underlying: Common Stock · 6,750 shares Expires 2026-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person December 14, 2018. Read SEC document
December 24, 2019 Filed Dec 27, 2019 16:59 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionStock Option(Right to Buy) · Derivative	15,986	$0.00 Strike: $12.58	$0.00	Disclosure SEC source: 0001179110-19-013163 · edgar.xml · derivative · entry 8 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,986 shares Expires 2025-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person December 14, 2018. Read SEC document
December 24, 2019 Filed Dec 27, 2019 16:59 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionStock Option (Right to Buy) · Derivative	1,454	$0.00 Strike: $13.02	$0.00	Disclosure SEC source: 0001179110-19-013163 · edgar.xml · derivative · entry 7 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,841 Underlying: Common Stock · 1,454 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person December 14, 2018. Read SEC document
December 24, 2019 Filed Dec 27, 2019 16:59 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionStock Option(Right to Buy) · Derivative	14,804	$0.00 Strike: $13.02	$0.00	Disclosure SEC source: 0001179110-19-013163 · edgar.xml · derivative · entry 6 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73 Underlying: Common Stock · 14,804 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person December 14, 2018. Read SEC document
December 24, 2019 Filed Dec 27, 2019 16:59 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionStock Option(Right to Buy) · Derivative	12,451	$0.00 Strike: $12.58	$0.00	Disclosure SEC source: 0001179110-19-013163 · edgar.xml · derivative · entry 5 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,451 shares Expires 2023-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person December 14, 2018. Read SEC document
December 24, 2019 Filed Dec 27, 2019 16:59 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	51,445	$20.00	$1,028,900.00	Disclosure SEC source: 0001179110-19-013163 · edgar.xml · nonDerivative · entry 4 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,443 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person December 14, 2018. Read SEC document
December 24, 2019 Filed Dec 27, 2019 16:59 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionCommon Stock	6,750	$10.83	$73,102.50	Disclosure SEC source: 0001179110-19-013163 · edgar.xml · nonDerivative · entry 3 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person December 14, 2018. Read SEC document
December 24, 2019 Filed Dec 27, 2019 16:59 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionCommon Stock	16,258	$13.02	$211,679.16	Disclosure SEC source: 0001179110-19-013163 · edgar.xml · nonDerivative · entry 2 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,138 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person December 14, 2018. Read SEC document
December 24, 2019 Filed Dec 27, 2019 16:59 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionCommon Stock	28,437	$12.58	$357,737.46	Disclosure SEC source: 0001179110-19-013163 · edgar.xml · nonDerivative · entry 1 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,880 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person December 14, 2018. Read SEC document
November 13, 2019 Filed Nov 14, 2019 18:11 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	557	$16.53	$9,207.21	Disclosure SEC source: 0001179110-19-011705 · edgar.xml · nonDerivative · entry 2 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,443 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $16.23 to $16.62. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
November 13, 2019 Filed Nov 14, 2019 18:11 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	62	$16.52	$1,024.24	Disclosure SEC source: 0001179110-19-011705 · edgar.xml · nonDerivative · entry 1 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.23 to $16.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
November 12, 2019 Filed Nov 13, 2019 17:11 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	169	$16.18	$2,734.42	Disclosure SEC source: 0001179110-19-011658 · edgar.xml · nonDerivative · entry 1 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,062 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
November 08, 2019 Filed Nov 12, 2019 16:21 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	337	$16.06	$5,412.22	Disclosure SEC source: 0001179110-19-011614 · edgar.xml · nonDerivative · entry 3 Manning Anthony M. · CIK 0001716468 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,231 F5 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.